BRIEF published on 01/19/2026 at 10:05, 11 days 6 hours ago Medios AG Enters Medicinal Cannabis Market European Market Medios AG Pharmaceutical Distribution Medicinal Cannabis Bedrocan Partnership
PRESS RELEASE published on 01/19/2026 at 10:00, 11 days 6 hours ago Medios AG enters market for medicinal cannabis Medios AG expands into medicinal cannabis market with exclusive distribution rights for Bedrocan products in Europe, strengthening expertise in oncology and neurology Pharmaceuticals Oncology Medios AG Medicinal Cannabis Bedrocan
BRIEF published on 11/11/2025 at 07:29, 2 months 19 days ago Medios AG Reports Robust Earnings Growth in Early 2025 EBITDA Revenue Growth Financial Performance Pharmaceuticals Medios AG
PRESS RELEASE published on 11/11/2025 at 07:24, 2 months 19 days ago Medios AG achieves strong growth in earnings and profit margin in the first nine months of 2025 Medios AG achieves 9.2% revenue growth and 26.1% increase in EBITDA pre1 in the first nine months of 2025. New CEO appointed. Outlook confirmed. Details in press release EBITDA Revenue Growth CEO Appointment Medios AG 2025 Outlook
BRIEF published on 11/03/2025 at 10:02, 2 months 27 days ago Thomas Meier Appointed CEO of Medios AG Growth Strategy CEO Appointment Medios AG Specialty Pharma Thomas Meier
PRESS RELEASE published on 11/03/2025 at 09:57, 2 months 27 days ago Thomas Meier becomes new CEO of Medios AG Thomas Meier appointed as new CEO of Medios AG effective February 1, 2026, succeeding Matthias Gaertner. Meier's past roles include CEO of Bachem Holding AG. Medios AG aims for further growth under his leadership CEO Appointment Medios AG Specialty Pharma Thomas Meier Bachem Holding AG
BRIEF published on 10/24/2025 at 11:09, 3 months 6 days ago Medios AG: Reallocation of Bencis Shares Medios AG Specialty Pharma Share Reallocation Bencis Capital Partners Janus Henderson Group
PRESS RELEASE published on 10/24/2025 at 11:04, 3 months 6 days ago Medios AG: Reallocation of Bencis shares Medios AG announces reallocation of Bencis shares to Janus Henderson, representing approximately 6.7% of share capital. Bencis sold shares acquired in 2024 through capital increase related to Ceban Pharmaceuticals B.V Janus Henderson Medios AG Specialty Pharma Bencis Shares Individualized Medicine
BRIEF published on 08/13/2025 at 07:42, 5 months 17 days ago Medios AG Reports Strong Growth in H1 2025 Revenue Growth Medios AG EBITDA Increase H1 2025 Pharmaceutical Segments
PRESS RELEASE published on 08/13/2025 at 07:37, 5 months 17 days ago Medios accelerates growth in the first half of 2025 and significantly increases earnings Medios accelerates growth in the first half of 2025, with revenue up by 9.3% to €991.7 million and EBITDA significantly increasing by 48.8%. Successful share buyback. Positive outlook for 2025 EBITDA Revenue Outlook Growth Medios
Published on 01/30/2026 at 14:00, 2 hours 15 minutes ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 40 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 14 hours ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 15 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/30/2026 at 16:00, 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:57, 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 18:00, 22 hours 15 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
